QUEST DIAGNOSTICS INCORPORATED for QUEST DIAGNOSTICS INCORPORATED
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Monitor implementation of H.R. 1865, Further Consolidated Appropriations Act, 2020, (Public Law 116-94) and provisions related to policies regarding data collection from laboratories under the Protecting Access to Medicare Act (PAMA). S. 2246, Allergy Testing Access Act of 2019, and H.R. 2009, the Removing Barriers to Allergy Diagnostic Tests Act, and provisions relating to Medicare and Medicaid coverage of allergy diagnostic tests.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHERRY HARPER WIDICUS | — |
Health Issues HCR
H.R. 6201, the Families First Coronavirus Response Act (Public Law 116-127), and provisions related to clinical laboratory testing for COVID-19, including coverage and reimbursement of COVID-19 diagnostic tests. H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act, the CARES Act, (Public Law 116-136), and provisions related to clinical laboratory testing for COVID-19, including coverage and reimbursement of COVID-19 diagnostic tests, laboratory data collection and reimbursement under PAMA, and laboratory data reporting. H.R.266, Paycheck Protection Program and Health Care Enhancement Act (Public Law 116-139), and provisions related to COVID-19 testing capacity. FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations as it relates to regulation and oversight of clinical laboratories, including laboratory-developed test services and pharmacogenetic testing. FY2021 CDC appropriations for improved pediatric reference intervals and harmonizing the reporting of clinical laboratory test results. Federal policy relating to implementation of anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Public Law 115-271. H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests. The Public Readiness and Emergency Preparedness Act (PREP Act) and COVID-19 liability protection for frontline health care providers, including CLIA-licensed laboratories and their personnel.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHERRY HARPER WIDICUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.